Max Robotics — Global Service Robot Directory + US Certification

About

Shiqiang Wu is a leading figure in the advancement of robot-assisted neurosurgery, with a focused expertise in stereotactic biopsy and the treatment of intracerebral hemorrhage. His research has fundamentally reshaped clinical approaches to brainstem tumor diagnosis and hypertensive intracerebral hemorrhage (HICH) management. Wu’s landmark 2020 study (35 citations) provided the first rigorous comparison of the Remebot robot-assisted frameless system against traditional frame-based stereotactic biopsy, demonstrating superior safety and efficiency. He further extended this work in 2023 (18 citations) to the uniquely challenging domain of brainstem tumors, proving that robot-assisted frameless biopsies are not only feasible but offer exceptional accuracy. In a parallel contribution to neurocritical care, his 2021 study (25 citations) established the clinical efficacy of combining robot-assisted neuroendoscopic hematoma evacuation with intracranial pressure monitoring for HICH, a protocol that has improved patient outcomes. Through these high-impact comparative studies, Wu has been instrumental in validating robotic platforms as a safer, faster, and more precise alternative to conventional techniques, setting a new standard for minimally invasive neurosurgery.